<scp>CT</scp> ‐ <scp>P39</scp> Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 StudySarbjit S. Saini, Clive Grattan, Ewa Springer et al.|Allergy|2025Cited by 28